Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 16/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.63 |
| ▸ | HRH1 | P35367 | 5/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.63 |
| ▸ | HRH2 | P25021 | 4/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | HTR1E | P28566 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129828 | 0.88 | TMEM97 (0.62) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL15861877 | 0.88 | TMEM97 (0.62) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL15861873 | 0.87 | TMEM97 (0.61) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL21800344 | 0.86 | TMEM97 (0.66) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL324086 | 0.85 | TMEM97 (0.64) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL15862044 | 0.85 | TMEM97 (0.56) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL15862185 | 0.85 | TMEM97 (0.58) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1506610 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1027341 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL31129893 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073803-B1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2018-09-19 | — | — | EP | disclosed |
| US-20180169117-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUTED PHENYL - (1,3-DIHYDRO-ISOINDOL-2-YL) - METHANONE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-2546233-B1 | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-2546233-B1 | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| EP-3119398-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUED PHENYL- (1, 3-DIHYDRO-ISOINDOL-2-YL) -METHANONE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-01-25 | — | — | EP | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169117-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUTED PHENYL - (1,3-DIHYDRO-ISOINDOL-2-YL) - METHANONE | SDHA, LDHA, ALDH5A1 | TMEM97 1340/4885SIGMAR1 1767/4885HRH1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.